Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29300207 | 0.90 | NMT2 (0.35) | NMT2NMT1GLP1RALDH1A1GPBAR1 | |
| SCHEMBL29299807 | 0.88 | ALDH1A1 (0.36) | NMT2NMT1GLP1RALDH1A1KDM4E | |
| SCHEMBL29300366 | 0.86 | DPP7 (0.39) | NMT2NMT1ALDH1A1KDM4EGPBAR1 | |
| SCHEMBL26533468 | 0.83 | KDM4E (0.43) | ALDH1A1KDM4EGPBAR1 | |
| SCHEMBL29300141 | 0.82 | GLP1R (0.33) | NMT2NMT1GLP1RALDH1A1GPBAR1 | |
| SCHEMBL29299844 | 0.82 | GLP1R (0.38) | NMT2NMT1GLP1RALDH1A1CAPN1 | |
| SCHEMBL29301977 | 0.81 | FOLH1 (0.43) | GLP1R | |
| SCHEMBL29302101 | 0.80 | GLP1R (0.43) | GLP1RALDH1A1 | |
| SCHEMBL9011923 | 0.77 | MEN1 (0.42) | NMT2NMT1ALDH1A1KDM4EGPBAR1 | |
| SCHEMBL22738631 | 0.77 | KDM4E (0.46) | ALDH1A1KDM4EGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | NMT2 1308/4885NMT1 1314/4885GLP1R 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.